Bahuleyan Biji, Menon Girish, Nair Suresh, Rao B R M, Easwer H V, Krishna Kumar
Department of Neurosurgery, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram 695 011, Kerala, India.
J Clin Neurosci. 2009 Nov;16(11):1421-4. doi: 10.1016/j.jocn.2009.03.024. Epub 2009 Aug 20.
Cystic prolactinomas are considered not amenable to dopamine agonist therapy. We present the results of dopamine agonist therapy in six patients with cystic prolactinomas. The inclusion criteria of patients were: (i) cystic macroadenomas with the cyst occupying more than 50% of the tumour volume; (ii) a serum prolactin value more than 150 ng/mL. All patients were males with a mean age of 35 years. The clinical presentations were erectile dysfunction in 66.6%, visual deficits in 50% and headache in 50% of patients. All patients were treated with bromocriptine only except one who was treated with both bromocriptine and cabergoline. The mean duration of follow up was 57.1 months. At the final follow-up 50% of patients had hormonal cure, 50% had radiological cure and 50% had reduction in the size of the tumour. Hence, it is appropriate to consider dopamine agonist therapy in patients with cystic prolactinomas before considering surgery.
囊性催乳素瘤被认为不适用于多巴胺激动剂治疗。我们展示了对6例囊性催乳素瘤患者进行多巴胺激动剂治疗的结果。患者的纳入标准为：（i）囊性大腺瘤，囊肿占肿瘤体积的50%以上；（ii）血清催乳素值超过150 ng/mL。所有患者均为男性，平均年龄35岁。临床表现为66.6%的患者有勃起功能障碍，50%的患者有视觉障碍，50%的患者有头痛。除1例同时接受溴隐亭和卡麦角林治疗外，所有患者仅接受溴隐亭治疗。平均随访时间为57.1个月。在最后一次随访时，50%的患者实现了激素治愈，50%的患者实现了影像学治愈，50%的患者肿瘤体积缩小。因此，在考虑手术之前，对囊性催乳素瘤患者考虑多巴胺激动剂治疗是合适的。
